Streetbeat News

Price Targets

COLL

Jefferies analyst Glen Santangelo downgraded Collegium Pharmaceutical (NASDAQ:COLL) from Buy to Hold while raising the price target from $30 to $37. This reflects a more cautious stance on the stock's current valuation but acknowledges potential upside.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:09 pm

CLAR

Jefferies analyst Randal Konik downgraded Clarus (NASDAQ:CLAR) from Buy to Hold and reduced the price target from $13 to $7, indicating a more cautious outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:07 pm

INMD

Barclays analyst Matt Miksic has maintained an Overweight rating on InMode (NASDAQ:INMD) but has reduced the price target from $45 to $33.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:06 pm

UNF

Baird analyst Andrew Wittmann has downgraded UniFirst (NYSE:UNF) from Outperform to Neutral and set a price target of $185. This change reflects a revised outlook on the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:03 pm

MODG

Raymond James analyst Joseph Altobello has maintained an Outperform rating on Topgolf Callaway Brands (NYSE:MODG) and increased the price target from $14 to $16.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:03 pm

REAL

Baird analyst Mark Altschwager has downgraded RealReal (NASDAQ:REAL) from Outperform to Neutral and reduced the price target from $3.25 to $2.75.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:02 pm

TYL

Tyler Technologies (NYSE:TYL) has been analyzed by 7 financial analysts, showing a range of opinions. Recent ratings include 3 bullish and 4 somewhat bullish, with an average 12-month price target of $480.00, a high of $510.00, and a low of $450.00, marking a 3.6% increase from the previous average of $463.33. Analyst actions include maintaining and raising ratings and price targets. Tyler Technologies offers software solutions for local government entities and has shown a revenue growth of 4.54% as of September 30, 2023. However, it faces challenges with below-average ROE and ROA, but has a strong net margin of 9.5% and a low debt-to-equity ratio of 0.28.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 1:00 pm

CNP

CenterPoint Energy (NYSE:CNP) received mixed ratings from 6 analysts, with 5 somewhat bullish and 1 somewhat bearish. The average 12-month price target is $29.17, down from $30.33, with a high of $32.00 and a low of $27.00. Analysts from Keybanc, Morgan Stanley, Barclays, JP Morgan, and BMO Capital have adjusted their ratings and price targets. CenterPoint's financials show a -2.26% revenue decline, a high net margin of 13.76%, an ROE of 2.67%, an ROA of 0.66%, and a debt-to-equity ratio of 1.91.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 1:00 pm

PFE

Pfizer (NYSE:PFE) has been analyzed by 17 analysts in the last three months, with a diverse range of perspectives. The average 12-month price target is $37.47, with a high of $75.00 and a low of $27.00, reflecting a 6.33% decline from the previous average. Recent actions by analysts show a trend of lowering price targets and maintaining or lowering ratings. Pfizer's financials indicate challenges with revenue growth, net margin, ROE, and ROA, but a positive aspect is its lower debt-to-equity ratio compared to the industry average.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 1:00 pm

RVLV

Baird analyst Mark Altschwager has downgraded Revolve Group (NYSE:RVLV) from Outperform to Neutral and set a price target of $17.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 1:00 pm